The only prospective, controlled, randomized, multicenter trial about anti-VEGF treatment for ROP—Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study—showed that bevacizumab was effective in treating ROP and was more effective than laser treatment in zone 1 ROP cases [5]. Here, VEGFA is linked to retinopathy of prematurity.